X4 Pharmaceuticals (XFOR) Q2 2024 earnings summary

Executive summary

• Achieved FDA approval and U.S. commercial launch of XOLREMDI (mavorixafor) for WHIM syndrome in April 2024, marking the company's first commercial product launch.

• Full commercial team deployed, with initial patients on therapy and positive feedback from distribution and patient support programs.

• Positive interim Phase 2 data for mavorixafor in chronic neutropenia announced in June 2024; pivotal global Phase 3 4WARD trial initiated.

• Sale of a Priority Review Voucher for $105 million in Q2 2024, significantly boosting cash reserves.

• Strong engagement with physicians, patient advocacy groups, and ongoing awareness campaigns to support WHIM syndrome and product adoption.

Financial highlights

• Net income of $90.8 million for Q2 2024, compared to a net loss of $55.7 million in Q2 2023, driven by a $105 million gain from the PRV sale and a $20.2 million non-cash gain from warrant remeasurement.

• Product revenue, net, was $0.6 million and cost of revenue was $0.3 million for Q2 2024, the first period with product sales.

• R&D expenses were $20.9 million (up from $15.6 million YoY); SG&A expenses were $13.3 million (up from $10.2 million YoY), both including $1.2 million in non-cash expenses.

• Cash, cash equivalents, restricted cash, and short-term marketable securities totaled $169.5 million as of June 30, 2024.

• Q2 2024 basic and diluted EPS: $0.45, compared to $(0.33) in Q2 2023.

Outlook and guidance

• Sufficient funds to support operations into late 2025, excluding potential future XOLREMDI revenue.

• Full Phase 2 data for mavorixafor in chronic neutropenia expected in November 2024; European regulatory submission for XOLREMDI planned by early 2025.

• Phase 3 FORWARD trial in chronic neutropenia is underway, targeting full enrollment by mid-2025; updates on enrollment progress expected in 2025.

• Additional capital may be required to finance operations beyond the next year; options include equity, debt, or strategic partnerships.